as attached

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.1%Reaction day

₹1352.00

prior close

₹1451.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+10.1% vs market

Pharmaceuticals peers, median of 158sector+0.2%+9.9% vs sector

On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

+0.1

15m

+0.4

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.1+0.1+10.1+0.2+9.9

Next day

+2.7+0.8+1.9+0.7+2.0

-0.7+0.7-1.3+0.5-1.2

+0.2+1.9-1.7+1.8-1.6

+0.7+2.1-1.4+1.9-1.2

+0.1+2.6-2.5+2.0-1.9

+2.1+1.2+1.0+1.2+1.0

15d

+1.0-0.1+1.2-0.6+1.6

+6.4+7.1-0.8+3.8+2.6

+8.3+8.2+0.1+7.9+0.4

-2.0+10.0-12.0+9.1-11.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences reported FY2026 consolidated revenue of Rs 3,129.42 crore, up 8.15% from Rs 2,893.64 crore in FY2025. Net profit surged 72.8% to Rs 647.51 crore versus Rs 374.67 crore last year, driven by a one-time deferred tax credit of Rs 150 crore from opting into the new concessional tax regime and improved operating margins (27.11% vs 24.89%). The Board declared an interim dividend of Rs 7.21 per share (721%) for FY2027. Exceptional items of Rs 17.24 crore were recorded due to increased gratuity and leave liabilities from new labour codes. The auditor gave an unmodified (clean) opinion.

Likely market impact

The strong PAT growth of 73% and margin expansion are positive signals for shareholders. The one-time tax benefit inflated profits; underlying operational performance showed steady improvement. The generous 721% dividend signals confidence in cash flows.